Vanguard Group Inc 2seventy Bio, Inc. Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
A detailed history of Vanguard Group Inc transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,731,679 shares of TSVT stock, worth $15.2 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,731,679
Previous 3,985,770
6.37%
Holding current value
$15.2 Million
Previous $17 Million
17.3%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding TSVT
# of Institutions
128Shares Held
47.8MCall Options Held
84.3KPut Options Held
53.7K-
Kynam Capital Management, LP Princeton, NJ5.95MShares$24.3 Million3.34% of portfolio
-
Morgan Stanley New York, NY4.36MShares$17.8 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY4.22MShares$17.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.91MShares$15.9 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY2.5MShares$10.2 Million0.17% of portfolio
About 2seventy bio, Inc.
- Ticker TSVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,873,600
- Market Cap $155M
- Description
- 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...